CGEM vs SPTX
CGEM: Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases. SPTX: Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics using its proprietary drug development platform.
Side-by-side fundamentals
| Metric | CGEM | SPTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $17.65 | $21.30 | |
| Market cap as of 2026-07-23 | $1.1B | $1.1B | |
| PEG as of 2026-07-23 | -0.24 | n/a | |
| Net margin as of 2026-07-23 | -346.2% | n/a | |
| Operating margin as of 2026-07-23 | -358.8% | n/a | |
| ROE as of 2026-07-23 | -51.4% | -24.2% | SPTX higher |
| ROA as of 2026-07-23 | -47.6% | -22.6% | SPTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 0.00 | -1.38 | |
| 1-year return as of 2026-07-22 close | +140.2% | +5.8% | CGEM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.